Does telmisartan or the combination of telmisartan and ramipril improve outcomes compared to ramipril in patients with vascular disease or high-risk diabetes?
Telmisartan is an effective alternative to ramipril with a lower risk of angioedema in high-risk vascular patients, but combining the two agents increases adverse events without added benefit.
Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101 ClinicalTrials.gov.).
The ONTARGET Investigators (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: